Elizabeth Simpson

Professor

The University of British Columbia
Country flagCanada

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Elizabeth Simpson is a faculty member at The University of British Columbia, Canada. Her research focuses on preclinical therapeutic assessments and gene editing technologies, particularly in the context of ocular diseases and genetic disorders. Recent contributions include studies on CRISPR/Cas9 applications, the effects of KDM5C on X-chromosome inactivation, and advancements in gene delivery methods.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Summary Cas9 transgenes can be employed for genome editing in mouse zygotes. However, using transgenic instead of exogenous Cas9 to produce gene‐edited animals creates unique issues including ill‐defined transgene integration sites, the potential for prolonged Cas9 expression in transgenic embryos, and increased genotyping burden. To overcome these issues, we generated mice harboring an oocyte‐specific, Gdf9 promoter driven, Cas9 transgene (Gdf9‐Cas9) targeted as a single copy into the Hprt1 locus. The X‐linked Hprt1 locus was selected because it is a defined integration site that does not influence transgene expression, and breeding of transgenic males generates obligate transgenic females to serve as embryo donors. Using microinjections and electroporation to introduce sgRNAs into zygotes derived from transgenic dams, we demonstrate that Gdf9‐Cas9 mediates genome editing as efficiently as exogenous Cas9 at several loci. We show that genome editing efficiency is independent of transgene inheritance, verifying that maternally derived Cas9 facilitates genome editing. We also show that paternal inheritance of Gdf9‐Cas9 does not mediate genome editing, confirming that Gdf9‐Cas9 is not expressed in embryos. Finally, we demonstrate that off‐target mutagenesis is equally rare when using transgenic or exogenous Cas9. Together, these results show that the Gdf9‐Cas9 transgene is a viable alternative to exogenous Cas9.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Elisa Marie Crombie

University College London

UNITED KINGDOM
View details

Rikke Hahn Kofoed

Aarhus University

DENMARK
View details

Wyeth Wasserman

Professor

The University of British Columbia

CANADA
View details

Jason D. Heaney

-

UNITED STATES
View details

Anthony Mathelier

University of Oslo

NORWAY
View details

Francesco DeMayo

National Institute of Environmental Health Sciences

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.